Ocugen (NASDAQ:OCGN) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Ocugen (NASDAQ:OCGN) from a sell rating to a hold rating in a research note issued to investors on Saturday.

Several other research analysts have also issued reports on the stock. Canaccord Genuity Group initiated coverage on shares of Ocugen in a research note on Tuesday, March 17th. They issued a “buy” rating and a $12.00 price target for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Ocugen in a research note on Thursday, January 22nd. Chardan Capital restated a “buy” rating and issued a $7.00 price objective on shares of Ocugen in a report on Thursday, March 5th. Finally, Oppenheimer assumed coverage on shares of Ocugen in a research note on Wednesday, March 11th. They set an “outperform” rating and a $10.00 target price for the company. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Ocugen Price Performance

Shares of OCGN stock opened at $2.04 on Friday. The stock has a market cap of $668.92 million, a price-to-earnings ratio of -8.87 and a beta of 2.75. The business’s fifty day moving average is $1.73 and its 200 day moving average is $1.51. Ocugen has a twelve month low of $0.56 and a twelve month high of $2.72. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 8.04.

Ocugen (NASDAQ:OCGN) last posted its quarterly earnings data on Wednesday, March 4th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.06). Ocugen had a negative return on equity of 2,626.38% and a negative net margin of 1,192.18%.The business had revenue of ($0.19) million during the quarter, compared to the consensus estimate of $0.86 million. Research analysts expect that Ocugen will post -0.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Cora Capital Advisors LLC boosted its position in shares of Ocugen by 27.5% during the fourth quarter. Cora Capital Advisors LLC now owns 30,143 shares of the company’s stock valued at $41,000 after buying an additional 6,500 shares during the last quarter. Jain Global LLC raised its position in Ocugen by 7.2% in the 4th quarter. Jain Global LLC now owns 114,690 shares of the company’s stock worth $155,000 after buying an additional 7,686 shares during the last quarter. Lanham O Dell & Company Inc. raised its position in Ocugen by 7.7% in the 3rd quarter. Lanham O Dell & Company Inc. now owns 140,000 shares of the company’s stock worth $228,000 after buying an additional 10,000 shares during the last quarter. Procyon Advisors LLC lifted its stake in Ocugen by 5.5% during the 3rd quarter. Procyon Advisors LLC now owns 211,100 shares of the company’s stock valued at $344,000 after acquiring an additional 11,000 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Ocugen by 56.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock valued at $36,000 after acquiring an additional 13,326 shares during the last quarter. Hedge funds and other institutional investors own 10.27% of the company’s stock.

Key Headlines Impacting Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Oppenheimer initiated coverage with an Outperform (Buy) rating and a $10 price target, calling Ocugen an emerging leader in gene therapy for blinding ocular disorders — a major analyst endorsement that can attract institutional interest. Oppenheimer Initiates Ocugen (OCGN) With a Buy Rating
• Positive Sentiment: Canaccord Genuity initiated coverage with a Buy rating and $12 price target, highlighting three clinical-stage retinal programs and “interesting” early data — another bullish analyst view that supports higher upside expectations. Canaccord Initiates Coverage of Ocugen, Inc. (OCGN) with a Buy Rating and a $12 Price Target
• Positive Sentiment: Ocugen announced it gained $15 million in a prior registered direct offering, extending its cash runway into 2027 — reduces immediate financing pressure and lowers short-term insolvency risk. Ocugen Gains $15 Million, Extends Cash Runway to 2027
• Neutral Sentiment: Analyst and trade commentary outlined a pipeline calendar of 2026–2027 catalysts (pivotal data, filings across three programs) that could drive large swings — important for timing but binary in outcome. OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
• Neutral Sentiment: Multiple outlets summarized the new coverage notes (Canaccord/Oppenheimer), increasing visibility but duplicating the same catalyst-driven narrative. Ocugen (OCGN) Receives a New Rating from Canaccord Genuity
• Negative Sentiment: Zacks flagged rising cash burn and dilution risk as Ocugen advances late‑stage programs — investors should expect financing needs and potential share issuance if data or revenue don’t materialize. Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
• Negative Sentiment: Short-term market reaction showed a share decline and underperformance in recent session(s), reflecting the tug-of-war between bullish analyst targets and financing/data risks. Ocugen Inc. stock falls Wednesday, underperforms market

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.